PRNewswire reports that Stryker‘s Endoscopy division has acquired Ivy Sports Medicine for an undisclosed amount.

According to the press release, Ivy Sports Medicine’s portfolio includes: the only FDA-approved collagen meniscus implant on the market; an all-inside repair device; and an inside-out meniscal suturing platform.

Ivy Sports Medicine describes its Collagen Mensicus Implant (CMI) as a completely absorbable implant made from a porous structure that serves as a guide for the body’s own cells in order to make use of the body’s own healing ability.

Regarding the acquisition, Matt Moreau, Vice President and General Manager of Stryker’s Sports Medicine business, said:

The acquisition of Ivy Sports Medicine strengthens our capabilities and fits strategically with our current portfolio. Ivy’s complete meniscal platform, coupled with their clinical history, will allow us to provide our customers with multiple solutions to address meniscal repair. This is an area of sports medicine where there is continued opportunity to address unmet customer needs. The Ivy portfolio provides a unique platform for us to build upon as we seek to continue advancing the treatment of meniscal injuries.

Ivy Sports Medicine is only one of Stryker’s several acquisitions during 2016. Some of Stryker’s others notable acquisitions include Sage Products, Physio-Control, Synergetics, SafeWire, and Stanmore Implants.